High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.

Cresswell, Fiona V; Meya, David B; Kagimu, Enock; Grint, Daniel; Te Brake, Lindsey; Kasibante, John; Martyn, Emily; Rutakingirwa, Morris; Quinn, Carson M; Okirwoth, Micheal; +10 more... Tugume, Lillian; Ssembambulidde, Kenneth; Musubire, Abdu K; Bangdiwala, Ananta S; Buzibye, Allan; Muzoora, Conrad; Svensson, Elin M; Aarnoutse, Rob; Boulware, David R; Elliott, Alison M; (2021) High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73 (5). pp. 876-884. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciab162

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1093/cid/ciab162

Abstract

Share

Download

Filename: High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficienc.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar